Final analysis of a randomized, double blind, phase II study of sorafenib with or without YIV-906 in patients with advanced HCC Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Yen, Y.; Harding, J. J.; Whang-Peng, J.; Shi, Y. K.; Yuen, M. F.; Li, X.; Gu, S.; Liu, C.; Jeng, L. B.; Yen, C. J.; Pan, C.; Chen, S. C.; Hsieh, J. C. H.; Saif, W. M.; Liu, S. H.; Li, F.; Lam, W.; Chu, E.; Cheng, Y. C. |
| Abstract Title: | Final analysis of a randomized, double blind, phase II study of sorafenib with or without YIV-906 in patients with advanced HCC |
| Meeting Title: | ESMO Gastrointestinal Cancers Congress Congress 2025 |
| Journal Title: | Annals of Oncology |
| Volume: | 36 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2025 Jul 2-5 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2025-07-01 |
| Start Page: | S72 |
| Language: | English |
| ACCESSION: | WOS:001545612500029 |
| DOI: | 10.1016/j.annonc.2025.05.185 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 172P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
